Kaspar Felix Bachmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Kaspar Felix Bachmann has a total of 142 co-authors. Here are the top co-authors by number of shared publications:
- Annika Reintam Blaser
Department of Anaesthesiology and Intensive Care University of Tartu Tartu Estonia
7 shared publications - David Berger
Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
7 shared publications Hansjörg Jenni
Department of Cardiovascular Surgery, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
5 shared publicationsDavid Berger
Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland
4 shared publicationsMatthias Haenggi
Department of Intensive Care Medicine, Inselspital, Bern University Hospital, University of Bern , Bern
4 shared publicationsBenjamin Hess
Department of Intensive Care, Luzerner Kantonsspital, Lucerne, Switzerland
3 shared publications
Latest Publications
- Open Access
- 14 November 2026
- Published by Springer Nature in World Journal of Emergency Surgery
Clinical algorithms for the diagnosis and management of acute mesenteric ischaemia: an international multidisciplinary consensus
- 14 November 2026
- Published by Springer Nature in World Journal of Emergency Surgery
Open AccessClinical algorithms for the diagnosis and management of acute mesenteric ischaemia: an international multidisciplinary consensus
- Open Access
- 6 November 2026
- Published by Springer Nature in World Journal of Emergency Surgery
International multidisciplinary consensus on the definition and nomenclature of acute mesenteric ischaemia: a modified Delphi study
- 6 November 2026
- Published by Springer Nature in World Journal of Emergency Surgery
Open AccessInternational multidisciplinary consensus on the definition and nomenclature of acute mesenteric ischaemia: a modified Delphi study
- Open Access
- 20 June 2026
- Published by Taylor & Francis in Biomarkers
- Vol. 31 (5) , 1-28
Potential time-sensitive biomarkers for the detection of acute mesenteric ischaemia: a systematic review of animal data
Acute mesenteric ischemia (AMI) is difficult to recognize and is often diagnosed late. Currently there are no established biomarkers that can assist in diagnosis or management. The present study was a systematic review of animal data, intended to identify potentially time-sensitive biomarkers for human AMI. A systematic literature search was conducted using PubMed, Web of Science, and Scopus up to 10/02/25. Studies assessing potential biomarkers of AMI in mammalian models, with timed responses from the onset of experimental ischemia were selected. Data quality was assessed using CAMARADES, and PRISMA guidelines were followed. Searches identified 2175 publications from which 342 were selected for full text review, and 61 papers describing 103 experiments on 53 potential biomarkers were analyzed. The models were very heterogeneous and a meaningful meta-analysis was not possible for any biomarker. However, a pragmatic list of biomarkers of potential value in AMI that could warrant investigation in humans has been formulated. Those proposed are D-lactate, intestinal fatty acid-binding protein, ischaemia-modified albumin, and signal peptide-CUB-EGF domain-containing protein 1. No single biomarker has provided unambiguous evidence to promote its use in clinical practice, but several may deserve further evaluation in future human studies.Study funding: Estonian Research Council, Grant PRG 1255.Study registration: PROSPERO CRD42023400888 (reference 400888).
- 20 June 2026
- Published by Taylor & Francis in Biomarkers
- Vol. 31 (5) , 1-28
Open AccessPotential time-sensitive biomarkers for the detection of acute mesenteric ischaemia: a systematic review of animal data
Acute mesenteric ischemia (AMI) is difficult to recognize and is often diagnosed late. Currently there are no established biomarkers that can assist in diagnosis or management. The present study was a systematic review of animal data, intended to identify potentially time-sensitive biomarkers for human AMI. A systematic literature search was conducted using PubMed, Web of Science, and Scopus up to 10/02/25. Studies assessing potential biomarkers of AMI in mammalian models, with timed responses from the onset of experimental ischemia were selected. Data quality was assessed using CAMARADES, and PRISMA guidelines were followed. Searches identified 2175 publications from which 342 were selected for full text review, and 61 papers describing 103 experiments on 53 potential biomarkers were analyzed. The models were very heterogeneous and a meaningful meta-analysis was not possible for any biomarker. However, a pragmatic list of biomarkers of potential value in AMI that could warrant investigation in humans has been formulated. Those proposed are D-lactate, intestinal fatty acid-binding protein, ischaemia-modified albumin, and signal peptide-CUB-EGF domain-containing protein 1. No single biomarker has provided unambiguous evidence to promote its use in clinical practice, but several may deserve further evaluation in future human studies.Study funding: Estonian Research Council, Grant PRG 1255.Study registration: PROSPERO CRD42023400888 (reference 400888).
- Open Access
- 27 November 2025
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 29 (2) , 159-168
Core outcome sets and trials of nutrition and metabolism interventions
Purpose of review: The target of critical care nutrition research is moving from short-term physiological surrogate endpoints and mortality toward long-term patient-centered outcomes. This review summarizes recent core outcome set (COS) initiatives relevant to nutrition and metabolism and outcome selection in recent trials. Recent findings: The Core Outcome Measures for Clinical Effectiveness Trials of Nutritional and Metabolic Interventions in Critical Illness (CONCISE) defined essential outcomes: survival, physical function, infection, activities of daily living, nutritional status, and muscle/nerve function to be assessed at 30 and 90 days after randomization, with suggested but nonmandated instruments to preserve feasibility. COSMOGI (core outcome set of daily monitoring of gastrointestinal function in critically ill patients) standardizes daily gastrointestinal monitoring during critical illness. Large, randomized trials testing higher protein or early aggressive energy delivery have not improved survival and functional recovery, although the latter has only recently received more attention. From a mechanistic perspective, outcome selection in critical care nutrition and gastrointestinal function research should prioritize patient-centered (i.e. functional and patient-reported) outcomes. Summary: Standardizing outcome selection should improve interpretability and evidence synthesis. Future trials should incorporate robust functional and patient-reported outcomes. Core outcome sets will need updates when new assessment tools (i.e., biomarkers, new functional tests, standardized ultrasound protocols) emerge.
- 27 November 2025
- Published by Wolters Kluwer Health in Current Opinion in Clinical Nutrition and Metabolic Care
- Vol. 29 (2) , 159-168
Open AccessCore outcome sets and trials of nutrition and metabolism interventions
Purpose of review: The target of critical care nutrition research is moving from short-term physiological surrogate endpoints and mortality toward long-term patient-centered outcomes. This review summarizes recent core outcome set (COS) initiatives relevant to nutrition and metabolism and outcome selection in recent trials. Recent findings: The Core Outcome Measures for Clinical Effectiveness Trials of Nutritional and Metabolic Interventions in Critical Illness (CONCISE) defined essential outcomes: survival, physical function, infection, activities of daily living, nutritional status, and muscle/nerve function to be assessed at 30 and 90 days after randomization, with suggested but nonmandated instruments to preserve feasibility. COSMOGI (core outcome set of daily monitoring of gastrointestinal function in critically ill patients) standardizes daily gastrointestinal monitoring during critical illness. Large, randomized trials testing higher protein or early aggressive energy delivery have not improved survival and functional recovery, although the latter has only recently received more attention. From a mechanistic perspective, outcome selection in critical care nutrition and gastrointestinal function research should prioritize patient-centered (i.e. functional and patient-reported) outcomes. Summary: Standardizing outcome selection should improve interpretability and evidence synthesis. Future trials should incorporate robust functional and patient-reported outcomes. Core outcome sets will need updates when new assessment tools (i.e., biomarkers, new functional tests, standardized ultrasound protocols) emerge.
- Open Access
- 9 July 2025
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 31 (5) , 599-607
Gastrointestinal function and nutritional interventions in septic shock
Purpose of review: Gastrointestinal (GI) dysfunction significantly impacts patient outcomes in septic shock, complicating clinical management due to its central role in systemic inflammation, barrier integrity, and nutrient assimilation. This review summarizes the evolving understanding of GI dysfunction during septic shock and provides an updated framework for clinical management. Recent findings: New insights from recent studies focus on individualized nutritional strategies over standardized calorie-driven targets, highlighting risks associated with aggressive enteral nutrition, such as exacerbation of gut ischemia and bowel distension, and microbial dysbiosis. Maintaining splanchnic perfusion, monitoring GI dysfunction with standardized tools, and advancing nutritional support progressively based on patient-specific gastrointestinal tolerance are current strategies. Novel adjunctive therapies targeting gut permeability and microbiome restoration have been proposed, yet robust clinical data remain limited. Summary: Clinical management should prioritize hemodynamic stabilization and organ support rather than immediately targeting any nutritional goals. Monitoring GI function systematically and tailoring nutritional interventions may prevent complications and support recovery. Future research should validate monitoring tools, refine individual patient assessment, and evaluate novel therapeutic interventions to improve patient-centered outcomes in septic shock.
- 9 July 2025
- Published by Wolters Kluwer Health in Current Opinion in Critical Care
- Vol. 31 (5) , 599-607
Open AccessGastrointestinal function and nutritional interventions in septic shock
Purpose of review: Gastrointestinal (GI) dysfunction significantly impacts patient outcomes in septic shock, complicating clinical management due to its central role in systemic inflammation, barrier integrity, and nutrient assimilation. This review summarizes the evolving understanding of GI dysfunction during septic shock and provides an updated framework for clinical management. Recent findings: New insights from recent studies focus on individualized nutritional strategies over standardized calorie-driven targets, highlighting risks associated with aggressive enteral nutrition, such as exacerbation of gut ischemia and bowel distension, and microbial dysbiosis. Maintaining splanchnic perfusion, monitoring GI dysfunction with standardized tools, and advancing nutritional support progressively based on patient-specific gastrointestinal tolerance are current strategies. Novel adjunctive therapies targeting gut permeability and microbiome restoration have been proposed, yet robust clinical data remain limited. Summary: Clinical management should prioritize hemodynamic stabilization and organ support rather than immediately targeting any nutritional goals. Monitoring GI function systematically and tailoring nutritional interventions may prevent complications and support recovery. Future research should validate monitoring tools, refine individual patient assessment, and evaluate novel therapeutic interventions to improve patient-centered outcomes in septic shock.
- Open Access
- 22 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-14
Electrolyte disorders in the critically ill: a retrospective analysis
Several electrolyte disorders have been associated with adverse outcomes, but data on the coincidence of multiple disorders, interactions between different electrolytes and the impact of substitution on electrolyte levels are scarce. This study aimed to describe electrolyte disorders’ prevalence, incidence, and interaction in a consecutive cohort of ICU patients. Single-center retrospective study, including 2,056 consecutive adult ICU patients. Patients without laboratory data, those declining participation, and those receiving renal replacement therapy were excluded. Electrolyte levels and intravenous electrolyte administration were analyzed during the first 96 h after ICU admission using descriptive statistics, regression models and AUC-ROC analysis. Of 2392 admitted patients, 2056 were included. On admission, 312 patients (15.2%) had no electrolytes measured, 316 (15.4%) did not have any electrolyte disorder, 643 (31.3%) had one disorder, and 785 (38.2%) had multiple disorders. The most common electrolyte disorders on admission were hyperchloremia (56.0%, 977/1,744), hyperkalemia (18.7%, 326/1,744), hypophosphatemia (16.8%, 293/1,744), and hyperphosphatemia (16.4%, 286/1,744). Most patients (77.4%, 1,592/2,056) developed at least one new disorder during their ICU stay. A considerable number of patients (19.7%, 344/1,744) experienced electrolyte disorders in both directions (‘hypo’ and ‘hyper’) during their ICU stay. Linear regression models revealed that changes in one electrolyte level are often associated with alterations in other electrolyte levels. Most patients (99.2% 2,039/2,056) received intravenous electrolytes. Electrolyte overcorrection occurred in 89/365 patients (24.4%) for hypokalemia and 50/575 patients (8.7%) for hypophosphatemia. AUC-ROC analysis revealed cut-off points with the highest sensitivity and specificity at 30 mmol of potassium within 6 h and 45 mmol of phosphate within 15 h. Electrolyte disorders are highly prevalent in ICU patients, with significant co-incidence and interplay between these disorders. Knowledge regarding overcorrection risks may inform safe electrolyte administration protocols.
- 22 April 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-14
Open AccessElectrolyte disorders in the critically ill: a retrospective analysis
Several electrolyte disorders have been associated with adverse outcomes, but data on the coincidence of multiple disorders, interactions between different electrolytes and the impact of substitution on electrolyte levels are scarce. This study aimed to describe electrolyte disorders’ prevalence, incidence, and interaction in a consecutive cohort of ICU patients. Single-center retrospective study, including 2,056 consecutive adult ICU patients. Patients without laboratory data, those declining participation, and those receiving renal replacement therapy were excluded. Electrolyte levels and intravenous electrolyte administration were analyzed during the first 96 h after ICU admission using descriptive statistics, regression models and AUC-ROC analysis. Of 2392 admitted patients, 2056 were included. On admission, 312 patients (15.2%) had no electrolytes measured, 316 (15.4%) did not have any electrolyte disorder, 643 (31.3%) had one disorder, and 785 (38.2%) had multiple disorders. The most common electrolyte disorders on admission were hyperchloremia (56.0%, 977/1,744), hyperkalemia (18.7%, 326/1,744), hypophosphatemia (16.8%, 293/1,744), and hyperphosphatemia (16.4%, 286/1,744). Most patients (77.4%, 1,592/2,056) developed at least one new disorder during their ICU stay. A considerable number of patients (19.7%, 344/1,744) experienced electrolyte disorders in both directions (‘hypo’ and ‘hyper’) during their ICU stay. Linear regression models revealed that changes in one electrolyte level are often associated with alterations in other electrolyte levels. Most patients (99.2% 2,039/2,056) received intravenous electrolytes. Electrolyte overcorrection occurred in 89/365 patients (24.4%) for hypokalemia and 50/575 patients (8.7%) for hypophosphatemia. AUC-ROC analysis revealed cut-off points with the highest sensitivity and specificity at 30 mmol of potassium within 6 h and 45 mmol of phosphate within 15 h. Electrolyte disorders are highly prevalent in ICU patients, with significant co-incidence and interplay between these disorders. Knowledge regarding overcorrection risks may inform safe electrolyte administration protocols.
- Open Access
- 31 March 2025
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 53 (7) , e1377-e1388
Adjunctive Sedation with Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy: A Pilot Randomized Controlled Study
Objectives: Septic encephalopathy (SE) occurs in up to 50% of critically ill patients with sepsis and is associated with a high mortality and morbidity. The pathophysiology of SE is complex and involves increased levels of inflammatory mediators. Commonly used sedative drugs, such as propofol and midazolam, may worsen neuronal inflammation. Dexmedetomidine (DEX) has been shown to decrease the production of inflammatory mediators in experimental models of sepsis. The aim of this study was to investigate the effect of DEX on biomarkers associated with SE in critically ill patients with sepsis. Design: Pilot, open-label, randomized controlled clinical trial. Setting: Single-center University Hospital, Switzerland. Patients: Adult patients with sepsis admitted to the ICU, who required intubation and ongoing sedative medication between September 1, 2019, and June 30, 2022. Interventions: DEX-based sedation compared with propofol and/or midazolam-based sedation and serum S100-β level at 48 hr after randomization. Measurements and Main Results: The study included 70 participants with 34 (48.6%) randomized to the DEX group and 36 (51.4%) to the propofol/midazolam group. Median S100-β levels in the DEX group at 48 hr were 0.103 (interquartile range 0.052–0.194) ng/ml, and in the propofol/midazolam group 0.189 (0.086–0.368) ng/mL (p = 0.064). Other biomarker showed no differences over time. In patients with a Glasgow Coma Scale less than or equal to 13, the median S100-β level in the DEX group was 0.13 ng/mL (0.06–0.18) compared to 0.91 ng/mL (0.43–0.96) in the propofol/midazolam group (p = 0.033). Conclusions: DEX-based sedation compared to propofol/midazolam-based sedation did not show any significant difference in S100-β or any other markers of SE in critically ill patients with sepsis requiring mechanical ventilation. The finding of lower S100-β levels in DEX-sedated patients with GCS less than 13 warrants further investigation.
- 31 March 2025
- Published by Wolters Kluwer Health in Critical Care Medicine
- Vol. 53 (7) , e1377-e1388
Open AccessAdjunctive Sedation with Dexmedetomidine for the Prevention of Severe Inflammation and Septic Encephalopathy: A Pilot Randomized Controlled Study
Objectives: Septic encephalopathy (SE) occurs in up to 50% of critically ill patients with sepsis and is associated with a high mortality and morbidity. The pathophysiology of SE is complex and involves increased levels of inflammatory mediators. Commonly used sedative drugs, such as propofol and midazolam, may worsen neuronal inflammation. Dexmedetomidine (DEX) has been shown to decrease the production of inflammatory mediators in experimental models of sepsis. The aim of this study was to investigate the effect of DEX on biomarkers associated with SE in critically ill patients with sepsis. Design: Pilot, open-label, randomized controlled clinical trial. Setting: Single-center University Hospital, Switzerland. Patients: Adult patients with sepsis admitted to the ICU, who required intubation and ongoing sedative medication between September 1, 2019, and June 30, 2022. Interventions: DEX-based sedation compared with propofol and/or midazolam-based sedation and serum S100-β level at 48 hr after randomization. Measurements and Main Results: The study included 70 participants with 34 (48.6%) randomized to the DEX group and 36 (51.4%) to the propofol/midazolam group. Median S100-β levels in the DEX group at 48 hr were 0.103 (interquartile range 0.052–0.194) ng/ml, and in the propofol/midazolam group 0.189 (0.086–0.368) ng/mL (p = 0.064). Other biomarker showed no differences over time. In patients with a Glasgow Coma Scale less than or equal to 13, the median S100-β level in the DEX group was 0.13 ng/mL (0.06–0.18) compared to 0.91 ng/mL (0.43–0.96) in the propofol/midazolam group (p = 0.033). Conclusions: DEX-based sedation compared to propofol/midazolam-based sedation did not show any significant difference in S100-β or any other markers of SE in critically ill patients with sepsis requiring mechanical ventilation. The finding of lower S100-β levels in DEX-sedated patients with GCS less than 13 warrants further investigation.
- 16 January 2025
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 71 (9) , e132
Estimation of Cardiac Output Under Venovenous Extracorporeal Membrane Oxygenation: Comparing Thermodilution Methods to 3D Echocardiography
- 16 January 2025
- Published by Wolters Kluwer Health in ASAIO Journal
- Vol. 71 (9) , e132
Estimation of Cardiac Output Under Venovenous Extracorporeal Membrane Oxygenation: Comparing Thermodilution Methods to 3D Echocardiography
- Open Access
- 18 December 2024
- Published by Springer Nature in Critical Care
- Vol. 28 (1) , 1-16
Core outcome set of daily monitoring of gastrointestinal function in adult critically ill patients: a modified Delphi consensus process (COSMOGI)
Gastrointestinal (GI) dysfunction is common in critically ill patients and associated with poor outcomes. There is a lack of standardised methods for daily monitoring of GI function. COSMOGI aimed to develop a Core Outcome Set (COS) for daily monitoring of GI function to improve consistency and comparability in future studies in critically ill patients. A modified Delphi consensus process engaging healthcare providers, clinical researchers, and patient representatives was performed. A systematic review identified existing parameters to monitor GI function, informing the development of potential outcomes. In Stage 1, participants rated outcomes (i.e., variables used for daily monitoring). In Stage 2, they refined and agreed on the definitions for the selected outcomes. The COS was ratified through consensus meetings. 368 individuals registered for the Delphi process. 285 participants (77.4%) completed Stage 1, and 181 participants (63.5%) completed Stage 2. From 77 potential outcomes, 13 essential outcomes for daily monitoring of GI function in studies, each with an agreed-upon definition, were established: abdominal distension, bowel dilatation, intra-abdominal pressure, abdominal pain, stool passage, vomiting, GI bleeding (upper and lower), use of parenteral nutrition due to intolerance of enteral nutrition, prokinetics, postpyloric feeding due to gastroparesis, lower GI paralysis, gastroparesis, intolerance to enteral nutrition. Using a modified Delphi consensus process, COSMOGI established a COS for monitoring GI function in critically ill patients in research. This COS and definitions provide a framework to guide future research, enabling comparability across studies and allowing for future definitions of GI dysfunction. Trial registration: This project was registered at ( www.comet-initiative.org ) on 27.03.2023 (number 2609) and was an ESICM-endorsed research project.
- 18 December 2024
- Published by Springer Nature in Critical Care
- Vol. 28 (1) , 1-16
Open AccessCore outcome set of daily monitoring of gastrointestinal function in adult critically ill patients: a modified Delphi consensus process (COSMOGI)
Gastrointestinal (GI) dysfunction is common in critically ill patients and associated with poor outcomes. There is a lack of standardised methods for daily monitoring of GI function. COSMOGI aimed to develop a Core Outcome Set (COS) for daily monitoring of GI function to improve consistency and comparability in future studies in critically ill patients. A modified Delphi consensus process engaging healthcare providers, clinical researchers, and patient representatives was performed. A systematic review identified existing parameters to monitor GI function, informing the development of potential outcomes. In Stage 1, participants rated outcomes (i.e., variables used for daily monitoring). In Stage 2, they refined and agreed on the definitions for the selected outcomes. The COS was ratified through consensus meetings. 368 individuals registered for the Delphi process. 285 participants (77.4%) completed Stage 1, and 181 participants (63.5%) completed Stage 2. From 77 potential outcomes, 13 essential outcomes for daily monitoring of GI function in studies, each with an agreed-upon definition, were established: abdominal distension, bowel dilatation, intra-abdominal pressure, abdominal pain, stool passage, vomiting, GI bleeding (upper and lower), use of parenteral nutrition due to intolerance of enteral nutrition, prokinetics, postpyloric feeding due to gastroparesis, lower GI paralysis, gastroparesis, intolerance to enteral nutrition. Using a modified Delphi consensus process, COSMOGI established a COS for monitoring GI function in critically ill patients in research. This COS and definitions provide a framework to guide future research, enabling comparability across studies and allowing for future definitions of GI dysfunction. Trial registration: This project was registered at ( www.comet-initiative.org ) on 27.03.2023 (number 2609) and was an ESICM-endorsed research project.
- Open Access
- 11 May 2024
- Published by Springer Nature in Journal of Intensive Care
- Vol. 12 (1) , 1-14
Mechanisms maintaining right ventricular contractility-to-pulmonary arterial elastance ratio in VA ECMO: a retrospective animal data analysis of RV–PA coupling
Background: To optimize right ventricular–pulmonary coupling during veno-arterial (VA) ECMO weaning, inotropes, vasopressors and/or vasodilators are used to change right ventricular (RV) function (contractility) and pulmonary artery (PA) elastance (afterload). RV–PA coupling is the ratio between right ventricular contractility and pulmonary vascular elastance and as such, is a measure of optimized crosstalk between ventricle and vasculature. Little is known about the physiology of RV–PA coupling during VA ECMO. This study describes adaptive mechanisms for maintaining RV–PA coupling resulting from changing pre- and afterload conditions in VA ECMO. Methods: In 13 pigs, extracorporeal flow was reduced from 4 to 1 L/min at baseline and increased afterload (pulmonary embolism and hypoxic vasoconstriction). Pressure and flow signals estimated right ventricular end-systolic elastance and pulmonary arterial elastance. Linear mixed-effect models estimated the association between conditions and elastance. Results: At no extracorporeal flow, end-systolic elastance increased from 0.83 [0.66 to 1.00] mmHg/mL at baseline by 0.44 [0.29 to 0.59] mmHg/mL with pulmonary embolism and by 1.36 [1.21 to 1.51] mmHg/mL with hypoxic pulmonary vasoconstriction (p < 0.001). Pulmonary arterial elastance increased from 0.39 [0.30 to 0.49] mmHg/mL at baseline by 0.36 [0.27 to 0.44] mmHg/mL with pulmonary embolism and by 0.75 [0.67 to 0.84] mmHg/mL with hypoxic pulmonary vasoconstriction (p < 0.001). Coupling remained unchanged (2.1 [1.8 to 2.3] mmHg/mL at baseline; − 0.1 [− 0.3 to 0.1] mmHg/mL increase with pulmonary embolism; − 0.2 [− 0.4 to 0.0] mmHg/mL with hypoxic pulmonary vasoconstriction, p > 0.05). Extracorporeal flow did not change coupling (0.0 [− 0.0 to 0.1] per change of 1 L/min, p > 0.05). End-diastolic volume increased with decreasing extracorporeal flow (7.2 [6.6 to 7.8] ml change per 1 L/min, p < 0.001). Conclusions: The right ventricle dilates with increased preload and increases its contractility in response to afterload changes to maintain ventricular–arterial coupling during VA extracorporeal membrane oxygenation.
- 11 May 2024
- Published by Springer Nature in Journal of Intensive Care
- Vol. 12 (1) , 1-14
Open AccessMechanisms maintaining right ventricular contractility-to-pulmonary arterial elastance ratio in VA ECMO: a retrospective animal data analysis of RV–PA coupling
Background: To optimize right ventricular–pulmonary coupling during veno-arterial (VA) ECMO weaning, inotropes, vasopressors and/or vasodilators are used to change right ventricular (RV) function (contractility) and pulmonary artery (PA) elastance (afterload). RV–PA coupling is the ratio between right ventricular contractility and pulmonary vascular elastance and as such, is a measure of optimized crosstalk between ventricle and vasculature. Little is known about the physiology of RV–PA coupling during VA ECMO. This study describes adaptive mechanisms for maintaining RV–PA coupling resulting from changing pre- and afterload conditions in VA ECMO. Methods: In 13 pigs, extracorporeal flow was reduced from 4 to 1 L/min at baseline and increased afterload (pulmonary embolism and hypoxic vasoconstriction). Pressure and flow signals estimated right ventricular end-systolic elastance and pulmonary arterial elastance. Linear mixed-effect models estimated the association between conditions and elastance. Results: At no extracorporeal flow, end-systolic elastance increased from 0.83 [0.66 to 1.00] mmHg/mL at baseline by 0.44 [0.29 to 0.59] mmHg/mL with pulmonary embolism and by 1.36 [1.21 to 1.51] mmHg/mL with hypoxic pulmonary vasoconstriction (p < 0.001). Pulmonary arterial elastance increased from 0.39 [0.30 to 0.49] mmHg/mL at baseline by 0.36 [0.27 to 0.44] mmHg/mL with pulmonary embolism and by 0.75 [0.67 to 0.84] mmHg/mL with hypoxic pulmonary vasoconstriction (p < 0.001). Coupling remained unchanged (2.1 [1.8 to 2.3] mmHg/mL at baseline; − 0.1 [− 0.3 to 0.1] mmHg/mL increase with pulmonary embolism; − 0.2 [− 0.4 to 0.0] mmHg/mL with hypoxic pulmonary vasoconstriction, p > 0.05). Extracorporeal flow did not change coupling (0.0 [− 0.0 to 0.1] per change of 1 L/min, p > 0.05). End-diastolic volume increased with decreasing extracorporeal flow (7.2 [6.6 to 7.8] ml change per 1 L/min, p < 0.001). Conclusions: The right ventricle dilates with increased preload and increases its contractility in response to afterload changes to maintain ventricular–arterial coupling during VA extracorporeal membrane oxygenation.